Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Reid Waldman, M.D., Chief Executive Officer of Veradermics

“This has been a defining year for Veradermics as we advanced the development of VDPHL01 as a potential treatment for pattern hair loss in both men and women. In men, we reported topline results from two positive registration-directed trials, Studies ‘302’ and ‘304’, which collectively enrolled more than 1,000 male participants and demonstrated early, consistent, and robust hair growth. We also announced positive topline results from Study ‘302’ Part B, which demonstrated a favorable safety and tolerability profile and achieved deepened or maintained hair growth at 12 months. VDPHL01 was generally well tolerated in both studies, with no treatment-related serious adverse events and no adverse events of special interest of cardiac origin observed. In women, we reported positive Phase 2 results in the open-label Study ‘207,’ and completed enrollment in the registration-directed Phase 2/3 Study ‘306,’ with topline data on track for the first half of 2027.”

Reid Waldman, M.D., Chief Executive Officer of Veradermics

“These accomplishments bring us closer to addressing a significant unmet need in pattern hair loss for both men and women. We remain well capitalized to continue the development of VDPHL01 and advance preparations for a potential commercial launch, with the goal of establishing VDPHL01, if approved, as a foundational treatment for pattern hair loss.”